Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG – Arjun Balar
In January 2020, pembrolizumab was approved for the treatment of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected to not undergo cystectomy. In this conversation, Arjun Balar, MD, and Petros Grivas, MD, Ph.D. discuss the use of pembrolizumab in the real-world…
